Reviewing Microbot Medical (NASDAQ:MBOT) & SANUWAVE Health (OTCMKTS:SNWV)

SANUWAVE Health (OTCMKTS:SNWV) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

42.5% of SANUWAVE Health shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 36.6% of SANUWAVE Health shares are held by company insiders. Comparatively, 4.7% of Microbot Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares SANUWAVE Health and Microbot Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SANUWAVE Health	$36.19 million	7.29	-$25.81 million	($4.56)	-6.76
Microbot Medical	N/A	N/A	-$10.74 million	($0.65)	-4.00

Microbot Medical has lower revenue, but higher earnings than SANUWAVE Health. SANUWAVE Health is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

SANUWAVE Health has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for SANUWAVE Health and Microbot Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SANUWAVE Health	0	0	0	0	0.00
Microbot Medical	0	0	1	0	3.00

Microbot Medical has a consensus target price of $9.00, suggesting a potential upside of 246.15%. Given Microbot Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Microbot Medical is more favorable than SANUWAVE Health.

Profitability

This table compares SANUWAVE Health and Microbot Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SANUWAVE Health	-1.33%	-23.83%	-20.60%
Microbot Medical	N/A	-218.30%	-158.17%

Summary

SANUWAVE Health beats Microbot Medical on 7 of the 13 factors compared between the two stocks.

About SANUWAVE Health

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's pulsed acoustic cellular expression systems, including dermaPACE system for treating diabetic foot ulcers and other chronic wounds; orthoPACE system for treating tendinopathies and acute and nonunion fractures; and Profile is used to provide solution for pain management in sports medicine and physical therapy. Its portfolio of wound treatment solutions provides patients with a noninvasive technology that boosts the body's normal healing and tissue regeneration processes. In addition, the company offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds. SANUWAVE Health, Inc. was founded in 2004 and is headquartered in Eden Prairie, Minnesota.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.